Saxagliptin improves glycaemic control and C‐peptide secretion in latent autoimmune diabetes in adults (LADA)
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: To assess the efficacy and tolerability of saxagliptin and C‐peptide secretion in patients with diagnosed type 2 diabetes classified as glutamic acid decarboxylase antibody (GADA)‐positive or GADA‐negative. Methods: Post hoc analysis of data pooled from five randomized, placebo‐controlled, 24‐week phase 3 studies (n = 2709) was conducted. We evaluated mean change from baseline at week 24 in HbA 1c, fasting plasma glucose, postprandial plasma glucose, fasting and postprandial C‐peptide, and HOMA2‐%β and the proportion of patients achieving HbA 1c < 7% (53 mmol/mol) at week 24. Results: Saxagliptin produced greater adjusted mean reductions from baseline in HbA 1c versus placebo for GADA‐negative [difference vs placebo (95% CI), −0.62% (−0.71% to −0.54%); −6.8 mmol/mol (−7.8, −5.9)] and GADA‐positive patients [−0.64% (−1.01% to −0.27%); −7.0 mmol/mol (−11.0, −3.0)]. Consistently, saxagliptin produced a greater reduction from baseline in fasting plasma glucose and postprandial plasma glucose versus placebo in GADA‐positive versus GADA‐negative patients, and more patients achieved HbA 1c < 7% (53 mmol/mol) with saxagliptin versus placebo in both GADA‐negative and GADA‐positive patients. Saxagliptin increased β‐cell function as assessed by HOMA2‐%β and postprandial C‐peptide area under the curve from baseline in patients in both GADA‐positive and GADA‐negative patients. Adverse events and hypoglycaemic events were similar across treatment groups and GADA categories. Conclusion: Saxagliptin was effective in lowering blood glucose levels and generally well tolerated in GADA‐positive patients. Interestingly, saxagliptin appears to improve β‐cell function in these patients, although a longer treatment duration may be needed to confirm this finding. Copyright © 2015 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“β-cell function was assessed in the postabsorptive phase via homeostasis model assessment (HOMA2-%β) using fasting C-peptide and plasma glucose [23].”
MethodSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“[32] and that increases in total daily insulin dose over time were lower with saxagliptin compared with placebo in patients requiring insulin therapy [22].”
BackgroundSelf-citationSteffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 4×
“Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that decreases glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) and is well tolerated in patients with type 2 diabetes when used as monotherapy [17,18] or in combination with commonly used diabetes medications su…”
BackgroundMethodInfluentialAdult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype
Hawa, M. I., Kolb, H., Schloot, N., Beyan, H., Paschou, S. A., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Beck-Neilsen, H., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0931 · Cited by 339
Self-citationZhou, Z., Xiang, Y., Ji, L., Jia, W., Ning, G., Huang, G., Yang, L., Lin, J., Liu, Z., Hagopian, W. A., et al. (2013) · Diabetes · doi:10.2337/db12-0207 · Cited by 251
Latent Autoimmune Diabetes in Adults
Naik, R. G., Brooks-Worrell, B. M., & Palmer, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1120 · Cited by 249
Buzzetti, R., Di Pietro, S., Giaccari, A., Petrone, A., Locatelli, M., Suraci, C., Capizzi, M., Arpi, M. L., Bazzigaluppi, E., Dotta, F., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1696 · Cited by 242
Self-citationBarnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162 · cited 2×
“[32] and that increases in total daily insulin dose over time were lower with saxagliptin compared with placebo in patients requiring insulin therapy [22].”
Background
Cited by
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
“In a post hoc analysis of pooled data from five randomized, placebocontrolled studies (n 5 2,709), saxagliptin improved b-cell function as assessed by HOMA2 of b-cell function and postprandial C-peptide from baseline in both GADApositive (n5 98) and GADA-negative subjects (n5 1,849) (67).”
MethodResultSelf-citationAdult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271
“Furthermore, a new autoantibody against the extracytoplasmatic (EC) IA-2EC(26-577) region can identify a novel antigenic determinant within the N terminus of the IA-2 protein76.”
BackgroundSelf-citationPast, present and future of latent autoimmune diabetes in adults
Liu, B., Xiang, Y., Liu, Z., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3205 · Cited by 50
Yan, X., Li, X., Liu, B., Huang, J., Xiang, Y., Hu, Y., Tang, X., Zhang, Z., Huang, G., Xie, Z., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01369-9 · Cited by 28
“Our data supports a previous post-hoc analysis of pooled type 2 diabetes trials that saxagliptin monotherapy led to a non-significant trend towards C-peptide preservation in LADA patients compared with those receiving placebo.(28) Further, compared with our previous trial of sitagliptin which showed a beneficial effec…”
Result
Metadata
- Authors
- Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N., & Hirshberg, B.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2015-10-28
- Volume
- 32
- Issue
- 3
- Pages
- 289-296
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1917326214
- Cited by
- 62
- References
- 9
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.